Orexo Ab Adr Stock Fundamentals
| ORXOY Stock | USD 2.60 0.00 0.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Orexo AB's long-term financial health and intrinsic value.
Orexo |
Orexo AB ADR OTC Stock Return On Equity Analysis
Orexo AB's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Orexo AB Return On Equity | -0.65 |
Most of Orexo AB's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orexo AB ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Orexo AB ADR has a Return On Equity of -0.6535. This is 97.27% lower than that of the sector and significantly lower than that of the Return On Equity industry. The return on equity for all United States stocks is 110.81% higher than that of the company.
Orexo AB ADR Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Orexo AB's current stock value. Our valuation model uses many indicators to compare Orexo AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Orexo AB competition to find correlations between indicators driving Orexo AB's intrinsic value. More Info.Orexo AB ADR is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Orexo AB by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Orexo AB's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Orexo Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orexo AB's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Orexo AB could also be used in its relative valuation, which is a method of valuing Orexo AB by comparing valuation metrics of similar companies.Orexo AB is currently under evaluation in return on equity category among its peers.
Orexo Fundamentals
| Return On Equity | -0.65 | |||
| Return On Asset | -0.0965 | |||
| Profit Margin | (0.28) % | |||
| Current Valuation | 76.98 M | |||
| Shares Outstanding | 34.35 M | |||
| Price To Earning | 17.22 X | |||
| Price To Book | 2.06 X | |||
| Price To Sales | 1.00 X | |||
| Revenue | 565 M | |||
| Gross Profit | 521.7 M | |||
| EBITDA | (141.3 M) | |||
| Net Income | (223.5 M) | |||
| Cash And Equivalents | 58.17 M | |||
| Cash Per Share | 1.68 X | |||
| Total Debt | 492.3 M | |||
| Debt To Equity | 1.76 % | |||
| Current Ratio | 2.05 X | |||
| Book Value Per Share | 1.38 X | |||
| Cash Flow From Operations | (229 M) | |||
| Number Of Employees | 126 | |||
| Beta | 0.72 | |||
| Market Capitalization | 58.73 M | |||
| Total Asset | 1.27 B | |||
| Working Capital | 70.5 M | |||
| Current Asset | 105.9 M | |||
| Current Liabilities | 35.4 M | |||
| Net Asset | 1.27 B |
About Orexo AB Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orexo AB ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orexo AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orexo AB ADR based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Orexo AB , a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Orexo AB was incorporated in 1994 and is headquartered in Uppsala, Sweden. OREXO AB is traded on OTC Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Orexo OTC Stock Analysis
When running Orexo AB's price analysis, check to measure Orexo AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orexo AB is operating at the current time. Most of Orexo AB's value examination focuses on studying past and present price action to predict the probability of Orexo AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orexo AB's price. Additionally, you may evaluate how the addition of Orexo AB to your portfolios can decrease your overall portfolio volatility.